DMXAA: an antivascular agent with multiple host responses (Q44234516)

1 December 2017

title

DMXAA: an antivascular agent with multiple host responses (English)

1 reference

1 December 2017

Bruce C Baguley

1

1 reference

1 December 2017

Lai Ming Ching

series ordinal

2

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

International Journal of Radiation Oncology Biology Physics

1 December 2017

published in

1 reference

1 December 2017

volume

54

1 reference

1 December 2017

issue

5

1 reference

1 December 2017

page(s)

1503-1511

1 reference

Vascular attack as a therapeutic strategy for cancer

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Fever and cancer in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Coley's toxins in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Endotoxin-mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Tumor necrosis factor (TNF).

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Influence of recombinant tumour necrosis factor alpha on blood flow and antibody localisation in human tumour xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512).

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Potential antitumor agents. 62. Structure-activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Vinca alkaloids: anti-vascular effects in a murine tumour

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

The effect of vinca alkaloids on tumour blood flow

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

In vitro methods for screening agents with an indirect mechanism of antitumour activity: xanthenone analogues of flavone acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Flavone acetic acid--preclinical and clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Plasma nitrate clearance in mice: modeling of the systemic production of nitrate following the induction of nitric oxide synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Different pathways of macromolecule extravasation from hyperpermeable tumor vessels

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Anti-tumour Effects of 5-hydroxytryptamine (5-HT) are Not Entirely Attributable to Its Effects on Tumour Vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Role of nitric oxide in angiogenesis and microcirculation in tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Potential of DMXAA combination therapy for solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903920-2

7 January 2021

10.1016/S0360-3016(02)03920-2

Identifiers

DOI

1 reference

release_ppsacxhbv5awnnpxp3gy66q2gi

1 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ppsacxhbv5awnnpxp3gy66q2gi

24 November 2022

mapped directly with Wikidata item

1 reference